Rhenman & Partners Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Rhenman & Partners Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.79M	Buy	91,100 +500	+0.6%	+$35K	0.64%	61
2026 Q1	$6.73M	Buy	90,600 +9,000	+11%	+$652K	0.83%	50
2025 Q4	$6.24M	Buy	+81,600	New	+$5.36M	0.58%	57
2024 Q4	–	Sell	-268,000	Closed	-$6.82M	–	93
2024 Q3	$6.82M	Buy	268,000 +83,500	+45%	+$2.19M	0.55%	57
2024 Q2	$4.67M	Buy	184,500 +80,000	+77%	+$2.19M	0.45%	56
2024 Q1	$3.23M	Sell	104,500 -30,500	-23%	-$1.04M	0.31%	65
2023 Q4	$5.45M	Hold	135,000	–	–	0.54%	58
2023 Q3	$3.56M	Hold	135,000	–	–	0.38%	61
2023 Q2	$2.32M	Hold	135,000	–	–	0.24%	72
2023 Q1	$2.32M	Buy	+135,000	New	+$1.57M	0.25%	74

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Rhenman & Partners Asset Management's BBIO Position: Q2 2026 in Review

Rhenman & Partners Asset Management increased its BridgeBio Pharma (BBIO) stake by 0.55% in Q2 2026, buying an estimated $35K and bringing the position to 91,100 shares worth $6.79M. The position accounts for 0.64% of the portfolio, ranked #61.

Rhenman & Partners Asset Management first reported a position in BBIO in Q1 2023 and has held it in 10 quarters since. The position peaked at $6.82M in Q3 2024. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Rhenman & Partners Asset Management held 91,100 shares of BridgeBio Pharma worth $6.79M as of Q2 2026.
Rhenman & Partners Asset Management bought 500 BridgeBio Pharma shares in Q2 2026, an estimated $35K.
BridgeBio Pharma made up 0.64% of Rhenman & Partners Asset Management's portfolio in Q2 2026, its #61 holding.
Rhenman & Partners Asset Management first reported a position in BridgeBio Pharma in Q1 2023 and has held it in 10 quarters since.
Rhenman & Partners Asset Management's BridgeBio Pharma position peaked at $6.82M in Q3 2024.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.